Initial experience with bosentan (Tracleer®) as treatment for pulmonary arterial hypertension (PAH) due to congenital heart disease in infants and young children

Zeitschrift fur Kardiologie

Volumn 94, Issue 9, 2005, Pages 570-574

  Gilbert, N ^a   Luther, Y C ^a   Miera, O ^a   Nagdyman, N ^a   Ewert, P ^a   Berger, F ^a   Lange, P E ^a   Schulze Neick, I ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

Bosentan; Competence network; Congenital heart disease; Hypertension; Infants; Pulmonary arterial

Indexed keywords

BOSENTAN;

ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; HEART FAILURE; HEART RIGHT VENTRICLE PRESSURE; HEART SURGERY; HEMODYNAMIC MONITORING; HUMAN; LABORATORY TEST; LIVER FUNCTION; MALE; PREOPERATIVE EVALUATION; PRESCHOOL CHILD; PULMONARY HYPERTENSION; STEADY STATE; TREATMENT CONTRAINDICATION;

ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; INFANT; MALE; PALLIATIVE CARE; PILOT PROJECTS; PULMONARY ARTERY; SULFONAMIDES; TREATMENT OUTCOME;

EID: 24644489695     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-005-0266-6     Document Type: Article

References (13)

1. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, Bingaman D, Nguyen N, Gaitonde M, van Giersbergen PL (2003) Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 73(4):372-382
2. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S (1995) Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 79(6):2122-2131
3. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69(4):223-231
4. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F (2003) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42(1):158-164
5. Krum H, Charlon V, Widmann T, Packer M (1999) Long-term, open-label experience with an endothelin receptor antagonist, bosentan, in patients with severe chronic heart failure. Circulation 100(Suppl I):646
6. Luscher TF, Barton M (2000) Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102(19):2434-2440
7. Mebazaa A, Karpati P, Renaud E, Algotsson L (2004) Acute right ventricular failure-from pathophysiology to new treatments. Intensive Care Med 30(2):185-196
8. Olschewski H, Seeger W, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Hoper MM, Behr J, Kleber FX (2000) Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Pneumologie 54(6):222-224
9. Peacock A, Naeije R, Galie N, Reeves JT (2004) End points in pulmonary arterial hypertension: the way forward. Eur Respir J 23(6):947-953
10. Rosenzweig EB, Kerstein D, Barst RJ (1999) Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99(14):1858-1865
11. Ross RD, Bollinger RO, Pinsky WW (1992) Grading the severity of congestive heart failure in infants. Pediatr Cardiol 13(2):72-75
12. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346(12):896-903
13. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, Tapson VF, Rubin LJ (2003) Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 124(1):247-254